ADIPOSE-DERIVED STEM CELLS (ASCS) FOR THE TREATMENT OF OSTEOCHONDRAL DEFECTS: COMPARISON BETWEEN HUMAN AND PORCINE ASCS FOR FUTURE PRE-CLINICAL MODELS
Arrigoni E., Lopa S., de Girolamo L., Stanco D., Brini A. (Milano) |
HUMAN ADIPOSE-DERIVED STEM CELLS (HASCS): A USEFUL TOOL TO SCREEN BIOMATERIALS FOR BONE REGENERATIOM
Lopa S., Arrigoni E., de Girolamo L., Stanco D., Chiesa R., Brini A. (Milano) |
DENTAL PULP MESENCHYMAL STEM CELLS PLASTICITY: A PROMISING TOOL IN DAMAGED TISSUES RESTORING
Sprio A., Di Scipio F., Raimondo S., Salamone P., Folino A., Geuna S., Di Carlo F., Berta G. (Orbassano TO) |
PREFERENTIAL KILLING OF CANCER CELLS USING SIC QDS
BARBERIS A., MARINO S., GELOEN A., LYSENKO V., MANCARDI D., MERLINO A., DI CARLO F., MOGNETTI B. (Orbassano TO, Lyon) |
PHARMACOGENETICS OF CITALOPRAM IN PALLIATIVE CARE OF CANCER
SCHILLANI G., GIRALDI T., CAPOZZO M., CONTE M. (Trieste, San Vito al Tagliamento PN) |
DISTRIBUTION OF CB2 CANNABINOID RECEPTOR POLYMORPHISMS IN AN ITALIAN POPULATION
Minocci D., Martino A., Massei J., Rossi A., Nieri P. (Pisa) |
DRUG RELATED-GENE POLYMORPHISMS MAY PREDICT SURVIVAL IN ESOPHAGEAL CANCER PATIENTS RECEIVING NEO-ADJUVANT RADIO-CHEMOTHERAPY
Bertolaso L., Gusella M., De Manzoni G., Bruscagin S., Stievano L., Zanoni A., Ferrazzi E., Cordiano C., Padrini R., Pasini F. (Rovigo, Verona, Padova) |
PRECLINICAL STUDIES OF COMBINATION OF GEMCITABINE AND VANDETANIB IN BLADDER TRANSITIONAL CANCER CELLS
Mey V., Ricciardi S., Del Tacca M., Danesi R. (Pisa) |
SYNERGISTIC CYTOTOXICITY AND MOLECULAR INTERACTION ON DRUG TARGETS OF SORAFENIB AND GEMCITABINE IN HUMAN PANCREAS CANCER AND NSCLC CELL LINES
Ricciardi S., Mey V., Pasqualetti G., Del Tacca M., Danesi R. (Pisa) |
ABCB1 POLYMORPHISMS ARE ASSOCIATED WITH CLOZAPINE PLASMA LEVELS IN PSYCHOTIC PATIENTS
Lastella M., Consoli G., Polillo M., Ciapparelli A., Ciofi L., Di Paolo A., Dell'Osso L., Del Tacca M., Danesi R. (Pisa) |
THIOPURINE S-METHYLTRANSFERASE PHARMACOGENETICS ON A LARGE-SCALE HEALTHY ITALIAN-CAUCASIAN POPULATION: DIFFERENCE IN ENZYME ACTIVITY
Serpe L., Calvo P., Muntoni E., D'Antico S., Giaccone M., Barbera C., Pera A., Ferretti C., Eandi M., Zara G., Canaparo R. (Torino) |
ASSOCIATION BETWEEN SNPS IN CLOCK GENES AND ANTICANCER DRUG TOXICITY
Caronno A., Pannacci M., Benfante R., Pirovano M., Fornasari D., Scaglione F. (Milano) |
CYP3A5 POLYMORPHISMS AND CARBAMAZEPINE PLASMA LEVELS IN EPILEPTIC PATIENTS
Magliulo L., Fallarini S., Viana M., Scordo M., Dahl M., Monaco F., Lombardi G. (Novara, Uppsala) |
ROLE OF GENETIC POLYMORPHISMS IN THE CLINICAL RESPONSE TO GLUCOCORTICOIDS IN PEDIATRIC INFLAMMATORY BOWEL DISEASES
De Iudicibus S., Londero M., Martelossi S., Stocco G., Decorti G., Bartoli F., Ventura A. (Trieste) |
GENETICS INTERACTIONS BETWEEN CITALOPRAM ANTIDEPRESSANT ACTIVITY AND MAO-A VNTR POLYMORPHISM IN PALLIATIVE CARE OF CANCER
Era D., Schillani G., Capozzo M., Conte M., Giraldi T. (Trieste, San Vito al Tagliamento PN) |
A GENETIC PERSPECTIVE TO THE RESPONSE TO PT-BASED CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS: TOWARD A CUSTOMIZED CHEMOTHERAPY.
Affatato A., Papi M., Valli M., Angelini S., Hrelia P., Ravaioli A., Cantelli Forti G. (Bologna, Rimini) |
PHARMACOKINETIC AND PHARMACODINAMIC EVALUATIONS OF METRONOMIC CHEMOTHERAPY WITH ORAL URACIL/TEGAFUR (UFT), CYCLOPHOSPHAMIDE (CTX) AND CELECOXIB (CXB) IN PRETREATED PATIENTS WITH ADVANCED GASTROINTESTINAL CANCERS
Di Desidero T., Allegrini G., Barletta M., Fioravanti A., Orlandi P., Canu B., Di Paolo A., Danesi R., Falcone A., Loupakis F., Masi G., Del Tacca M., Bocci G. (Pisa, Livorno, Pontedera PI) |
CLINICAL TRIALS ON “NON PHARMACEUTICAL PRODUCTS” , A NEW ASPECT OF EVIDENCE BASED MEDICINE.
Nunziata A., Bianco S. (Pomezia RM) |
RECURRENT URETHRAL STENOSIS: A PILOT CLINICAL STUDY OF LOCAL PACLITAXEL TREATMENT.
Robbiano L., Fucile C., Marini V., Gallo F., Giberti C., Martelli A., Mattioli F. (Genova, Savona) |